In an emerging area of medical research, mental health is increasingly recognized as a critical factor influencing physical health outcomes. A recent study presented at the American College of Surgeons (ACS) Clinical Congress 2025 in Chicago sheds new light on how depression affects surgical recovery specifically in older adults undergoing cancer surgeries. This groundbreaking research, conducted by scientists at The Ohio State University and its Wexner Medical Center, focuses on the intersection of depression with colorectal, hepatobiliary, and pancreatic cancer surgeries. The findings offer compelling evidence that depression not only complicates recovery but that effective treatment with antidepressants can substantially improve postoperative outcomes and reduce healthcare costs.

Depression, a pervasive psychiatric disorder characterized by persistent sadness, loss of interest, and impaired cognitive function, has been long associated with adverse physical health effects, including disrupted sleep patterns, weakened immune function, and increased susceptibility to chronic diseases. The relationship between depression and cancer has been an active topic of investigation, with studies linking depression to heightened cancer risk and poorer disease prognosis. However, its specific influence on surgical outcomes has remained less explored until now.

The study utilizes extensive retrospective analysis using data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. By reviewing records of older patients diagnosed with colorectal, hepatobiliary, and pancreatic cancers, the researchers aimed to understand how a concurrent diagnosis of depression, within a 12-month window before or after cancer diagnosis, impacted post-surgical recovery. An important methodological innovation was the use of Medicare Part D prescription data to identify which patients had received antidepressant medications, enabling a distinction between treated and untreated depression in the surgical context.

The research cohort consisted of 32,726 patients, of which 1,731 were diagnosed with depression. Among these, 1,253 patients were prescribed antidepressants, while 478 were not. This stratification allowed the researchers to compare surgical outcomes across three groups: patients without depression, patients with treated depression, and patients with untreated depression. This granular approach provides richer insight into how pharmacologic management of depression interfaces with surgical resilience and recovery.

Outcomes were rigorously defined in terms of an “ideal” postoperative course, which included the absence of surgical complications, avoidance of protracted hospital stays, no readmissions within 90 days, and survival beyond 90 days post-surgery. This composite endpoint highlights a clinically meaningful benchmark emphasizing quality recovery rather than isolated metrics. The study’s findings demonstrate that patients suffering from depression, regardless of treatment status, generally experience poorer recovery trajectories compared to those without depression.

However, the data revealed a significant mitigating effect of antidepressant therapy. Patients receiving pharmacological treatment for depression exhibited notably better outcomes compared to their untreated counterparts. These improvements extended beyond clinical markers to include shorter hospital stays, reduced readmission rates, and lower postoperative mortality rates. Such findings underscore the potential of antidepressants not only to alleviate psychiatric symptoms but to foster physiological resilience during the vulnerable perioperative period.

The economic implications were equally striking. Patients without depression had the lowest average cost of surgical care, calculated at approximately $17,551. Those with treated depression experienced a modest increase of 7.3% in healthcare expenditures, while costs soared by over 10% for patients with untreated depression. This correlation between mental health treatment and reduced financial burden provides a compelling argument for integrating psychiatric care into surgical protocols, possibly alleviating strain on healthcare systems burdened by costly postoperative complications.

Exploring the potential mechanisms behind these observations, the investigators point to the well-documented tendency of depression to reduce adherence to medical regimens, including both pharmacological treatments and recommended lifestyle interventions. Depression’s detrimental impact on motivation and executive functioning may hinder patients’ ability to participate actively in their care plans, jeopardizing recovery. By treating depression, healthcare providers can potentially enhance patient engagement, promote self-care, and improve compliance with postoperative guidelines, thereby leading to better outcomes.

Furthermore, the impetus for this research emerged during the COVID-19 pandemic, which dramatically heightened awareness of mental health issues worldwide. The pandemic underscored the complex interplay between psychosocial stressors and physical illness, prompting researchers at The Ohio State University to investigate how mental health intersected with surgical outcomes. Recognizing health-related social needs, including food insecurity, job instability, and domestic violence, the team sought a broader understanding of the factors influencing recovery beyond purely biomedical variables.

While the study highlights the need for systematic depression screening in surgical candidates, it also acknowledges certain limitations. The use of antidepressant prescriptions as a proxy for depression treatment does not capture non-pharmacological interventions, such as psychotherapy or psychiatric care, which may also impact outcomes. In addition, the retrospective design limits causative conclusions, and future prospective studies are needed to validate these findings and explore the nuanced effects of different types and durations of depression management.

Importantly, the senior author, Dr. Timothy M. Pawlik, emphasizes that integrating mental health evaluation into preoperative planning could empower surgeons and healthcare teams to craft holistic, individualized treatments. Addressing psychological comorbidities proactively may help anticipate complications, reduce morbidity and mortality, and optimize patient-centered care. Patients are encouraged to acknowledge and communicate their mental health needs as part of their surgical journey to achieve the best possible recovery.

This study represents a significant step toward bridging the gap between mental and physical health in surgical oncology, demonstrating that effective psychiatric treatment is not just beneficial for mood symptoms but is a critical component of improving survival and recovery after complex cancer surgeries. The findings resonate with a growing movement to view patient care through a biopsychosocial lens, advocating for interdisciplinary approaches that address the whole patient, rather than isolated disease processes.

In conclusion, depression substantially hampers recovery after major abdominal cancer surgeries in older adults. Nonetheless, antidepressant treatment appears to mitigate these effects, resulting in better surgical outcomes, shorter hospital stays, decreased readmissions, lower mortality, and reduced healthcare costs. This data underscores the imperative to prioritize mental health screening and intervention as integral aspects of perioperative care. As the healthcare community moves toward more comprehensive patient care models, such evidence could catalyze protocol changes that improve quality of life and survival rates for vulnerable populations.

Subject of Research: Impact of depression and antidepressant treatment on surgical outcomes in patients with colorectal, hepatobiliary, and pancreatic cancers.

Article Title: The Impact of Antidepressants on Surgical Outcomes in Patients with Abdominal Cancer and Comorbid Depression

News Publication Date: October 3, 2025

Web References:
– American College of Surgeons Clinical Congress 2025: https://www.facs.org/for-medical-professionals/conferences-and-meetings/clinical-congress-2025/
– Depression and sleep disruption: https://www.tandfonline.com/doi/full/10.31887/DCNS.2008.10.3/dnutt
– Depression and cancer risk: https://www.mdpi.com/2076-3425/13/2/302

References: Katayama E, et al. The Impact of Antidepressants on Surgical Outcomes in Patients with Abdominal Cancer and Comorbid Depression, Scientific Forum, American College of Surgeons (ACS) Clinical Congress 2025.

Keywords: Depression, Surgery, Antidepressants, Cancer, Colorectal Cancer, Hepatobiliary Cancer, Pancreatic Cancer, Surgical Outcomes, Postoperative Recovery, Healthcare Costs, Mental Health, Perioperative Care

Utilizing a rich dataset merging the Massachusetts Cancer Registry with credit bureau data between 2010 and 2019, researchers meticulously tracked the credit trajectories of 42,451 individuals diagnosed with cancer. Approximately 8.5% of these patients developed financial toxicity within 18 months post-diagnosis, evidenced by a credit score falling below 600, while an additional 3% entered the study already in this vulnerable category. Massachusetts’ near-universal healthcare coverage of 97-98% furthermore suggests that the impact of financial toxicity on mortality could be even more pronounced in states with less extensive healthcare access.

The study’s principal finding reveals a stark correlation between credit score deterioration and increased risk of death. Patients who experienced a two-tier drop in credit score within a year exhibited a 29% higher likelihood of mortality compared to those with stable scores. More granularly, data from any given six-month interval following diagnosis demonstrated a 12% increased risk of death associated with a one-tier drop, and a dramatic 63% heightened risk tied to a two-tier decrement. This dose-response relationship underscores the toxic interplay between financial instability and patient outcomes.

Interestingly, the research highlights that improvement in credit ratings post-diagnosis does not translate into a protective effect against mortality. This asymmetry in the data suggests that while financial decline exacerbates vulnerability, recovery from financial setbacks may not sufficiently counterbalance the health detriments incurred during critical periods following cancer diagnosis. This finding challenges widely held assumptions about financial recovery and health outcomes, opening new avenues for investigation.

Delving into demographic variables, the study identifies that younger patients, particularly those aged 21 to 44, bear a disproportionate burden of financial toxicity. Racial disparities are also stark, with Black and Hispanic individuals more susceptible to adverse financial trajectories post-diagnosis. These disparities may be reflective of systemic inequities in healthcare accessibility, employment stability, and social support structures that compound the challenges faced by marginalized groups in managing the economic burdens of cancer treatment.

Socioeconomic determinants further delineate high-risk groups. Individuals who are separated or divorced, possess less than a college education, are current smokers, rely on public insurance, or reside in communities with elevated poverty—measured by the Area Deprivation Index’s >5% poverty threshold—are more prone to suffering financial toxicity. These intersecting vulnerabilities chart a complex social landscape where economic distress worsens health trajectories, suggesting a multi-dimensional approach is essential for mitigating risk.

Income disparity emerges as a crucial factor, with patients earning below $30,000 annually experiencing odds of financial toxicity more than triple those of individuals in the $50,000-$69,000 bracket. This finding highlights the devastating financial consequences in lower-income groups, emphasizing an urgent need for tailored socioeconomic interventions to support cancer patients at heightened risk.

Lead investigator Dr. Benjamin C. James, affiliated with Harvard Medical School and Beth Israel Deaconess Medical Center, emphasizes the clinical implications of these findings: “Our work shows that as somebody’s credit score drops, their mortality risk increases. This gives providers one more data point to intervene upon.” Dr. James underscores the potential for integrating financial health monitoring into cancer care protocols, aiming to inform more holistic patient management strategies that address both medical and socioeconomic vulnerabilities.

The research team, including experts across surgical oncology, public health, and medical economics, stresses that the observed mortality risk is not merely a function of psychological stress but a tangible clinical outcome linked to financial destabilization. These findings broaden the scope of “financial toxicity” beyond economic hardship to encompass its lethal consequences on patient survival—a critical public health insight that demands attention.

Moreover, the study challenges the healthcare community to consider financial toxicity as an objective, quantifiable risk factor in cancer treatment plans. While access to care is often cited in health disparities, this research distinctly illustrates that financial toxicity contributes independently to worsened outcomes, irrespective of insurance coverage extent. This revelation calls for innovative interventions targeting economic stability alongside conventional therapeutic approaches.

As the research was conducted in a state with exceptional healthcare accessibility, the authors cautiously infer that in regions with lower coverage rates, financial toxicity’s impact on mortality could be even more severe. This geographic variability underscores the need for nationwide strategies to alleviate economic barriers in cancer care, facilitating equitable outcomes across diverse populations.

While the study awaits peer review, its presentation at the prestigious American College of Surgeons Clinical Congress signifies its importance and relevance in surgical oncology discourse. The findings pave the way for future longitudinal and interventional studies designed to craft evidence-based policies that integrate financial well-being as a critical component of cancer survivorship.

In sum, this pioneering analysis reveals an unsettling but incontrovertible connection: financial distress, as manifested by dropping credit scores, materially escalates the risk of death among cancer patients. Beyond the realms of medical treatment, the economic ramifications of cancer serve as a parallel adversary, demanding urgent clinical and policy responses to holistically improve patient survival and quality of life.

Subject of Research: Financial toxicity and its impact on mortality risk among cancer patients

Article Title: Not specified in the original content

News Publication Date: Not specified in the original content

Web References:

• American College of Surgeons Clinical Congress 2025: https://www.facs.org/for-medical-professionals/conferences-and-meetings/clinical-congress-2025/
• American College of Surgeons: https://www.facs.org/

References:
James BC, et al. Factors Associated with Financial Toxicity in Surgical Cancer Care, Scientific Forum, American College of Surgeons (ACS) Clinical Congress 2025.

Image Credits: Not provided

Keywords: Cancer, Cancer research, Oncology, Cancer policy, Cancer patients